162 related articles for article (PubMed ID: 16185074)
1. Cys114-linked dimers of transthyretin are compatible with amyloid formation.
Karlsson A; Olofsson A; Eneqvist T; Sauer-Eriksson AE
Biochemistry; 2005 Oct; 44(39):13063-70. PubMed ID: 16185074
[TBL] [Abstract][Full Text] [Related]
2. Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form.
Lindhagen-Persson M; Vestling M; Reixach N; Olofsson A
Amyloid; 2008 Dec; 15(4):240-5. PubMed ID: 19065295
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
4. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro.
McCutchen SL; Kelly JW
Biochem Biophys Res Commun; 1993 Dec; 197(2):415-21. PubMed ID: 8267575
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
6. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
7. Antibody therapy for familial amyloidotic polyneuropathy.
Su Y; Jono H; Torikai M; Hosoi A; Soejima K; Guo J; Tasaki M; Misumi Y; Ueda M; Shinriki S; Shono M; Obayashi K; Nakashima T; Sugawara K; Ando Y
Amyloid; 2012 Jun; 19 Suppl 1():45-6. PubMed ID: 22506915
[TBL] [Abstract][Full Text] [Related]
8. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.
Ando Y; Terazaki H; Nakamura M; Ando E; Haraoka K; Yamashita T; Ueda M; Okabe H; Sasaki Y; Tanihara H; Uchino M; Inomata Y
Transplantation; 2004 Feb; 77(3):345-9. PubMed ID: 14966406
[TBL] [Abstract][Full Text] [Related]
9. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M
Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296
[TBL] [Abstract][Full Text] [Related]
10. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization.
Raghu P; Reddy GB; Sivakumar B
Arch Biochem Biophys; 2002 Apr; 400(1):43-7. PubMed ID: 11913969
[TBL] [Abstract][Full Text] [Related]
13. Stability and fibril formation properties of human and fish transthyretin, and of the Escherichia coli transthyretin-related protein.
Lundberg E; Olofsson A; Westermark GT; Sauer-Eriksson AE
FEBS J; 2009 Apr; 276(7):1999-2011. PubMed ID: 19250316
[TBL] [Abstract][Full Text] [Related]
14. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
Morais-de-Sá E; Neto-Silva RM; Pereira PJ; Saraiva MJ; Damas AM
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):512-9. PubMed ID: 16627944
[TBL] [Abstract][Full Text] [Related]
15. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
16. Structure and assembly-disassembly properties of wild-type transthyretin amyloid protofibrils observed with atomic force microscopy.
Pires RH; Saraiva MJ; Damas AM; Kellermayer MS
J Mol Recognit; 2011; 24(3):467-76. PubMed ID: 21504025
[TBL] [Abstract][Full Text] [Related]
17. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity.
Ferreira N; Cardoso I; Domingues MR; Vitorino R; Bastos M; Bai G; Saraiva MJ; Almeida MR
FEBS Lett; 2009 Nov; 583(22):3569-76. PubMed ID: 19861125
[TBL] [Abstract][Full Text] [Related]
18. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis and therapy for transthyretin related amyloidosis].
Ando Y; Jono H
Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
[TBL] [Abstract][Full Text] [Related]
20. Surface exposed epitopes and structural heterogeneity of in vivo formed transthyretin amyloid fibrils.
Bergström J; Engström U; Yamashita T; Ando Y; Westermark P
Biochem Biophys Res Commun; 2006 Sep; 348(2):532-9. PubMed ID: 16893521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
